Oral dopamine agonists are effective for treating early Parkinson's disease (PD). Rotigotine is a dopamine agonist delivered through a silicone-based transdermal patch that is replaced every 24 hours.
Objectives
To assess the efficacy and safety of rotigotine in patients with PD not receiving dopaminergic medications.
Treatment with patches containing either 4.5, 9.0, 13.5, or 18.0 mg of rotigotine or placebo for 11 weeks.
Main Outcome Measure
The change in the sum of the scores of the activities of daily living and motor components of the Unified Parkinson's Disease Rating Scale from baseline to the end of treatment.
Results
There was a significant dose-related improvement in the motor and activities of daily living Unified Parkinson's Disease Rating Scale score between baseline and week 11 for the 13.5- and 18.0-mg groups compared with placebo (placebo, 0.3 ± 7.7; 13.5-mg group, 5.1 ± 7.0,P= .001; 18.0-mg group, 5.3 ± 7.0,P<.001). Adverse experiences that occurred more commonly among subjects randomized to active treatment vs placebo included nausea, application site reactions, dizziness, insomnia, somnolence, vomiting, and fatigue.
Conclusions
Rotigotine can be safely administered once daily transdermally and improves parkinsonian signs in patients with early PD.
Год издания:2003
Издательство:American Medical Association
Источник:Archives of Neurology
Ключевые слова:Parkinson's Disease Mechanisms and Treatments, Conducting polymers and applications
